Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Patient characteristics initiating ocrelizumab (OCR) in a real-world setting

Trial Profile

Patient characteristics initiating ocrelizumab (OCR) in a real-world setting

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2018

At a glance

  • Drugs Ocrelizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Oct 2018 New trial record
    • 12 Oct 2018 Results evaluating the potential of misclassification using an existing algorithm identifying relapse in insurance claims for multiple sclerosis (MS) patients receiving ocrelizumab presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 12 Oct 2018 Results describing patient characteristics from a large insurance claims database presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top